Mak Capital One LLC Purchases Shares of 1,448,461 Day One Biopharmaceuticals, Inc. $DAWN

Mak Capital One LLC acquired a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,448,461 shares of the company’s stock, valued at approximately $10,212,000. Day One Biopharmaceuticals comprises about 1.6% of Mak Capital One LLC’s holdings, making the stock its 9th biggest holding.

Other large investors have also recently modified their holdings of the company. AIGH Capital Management LLC purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter valued at about $10,719,000. AlphaQuest LLC increased its stake in Day One Biopharmaceuticals by 1,065.6% in the 3rd quarter. AlphaQuest LLC now owns 185,006 shares of the company’s stock worth $1,304,000 after purchasing an additional 169,134 shares during the period. Schroder Investment Management Group purchased a new position in Day One Biopharmaceuticals in the 2nd quarter worth approximately $1,171,000. Geode Capital Management LLC lifted its position in Day One Biopharmaceuticals by 11.2% in the second quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock valued at $11,132,000 after purchasing an additional 171,964 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd lifted its position in Day One Biopharmaceuticals by 71.7% in the second quarter. Dynamic Technology Lab Private Ltd now owns 83,223 shares of the company’s stock valued at $541,000 after purchasing an additional 34,766 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Transactions at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 6,065 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $70,354.00. Following the completion of the sale, the chief financial officer directly owned 312,025 shares of the company’s stock, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Adam Dubow sold 6,395 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the sale, the insider directly owned 72,694 shares in the company, valued at $843,250.40. The trade was a 8.09% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 36,461 shares of company stock worth $422,948. 6.20% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Stock Performance

DAWN opened at $21.36 on Tuesday. The stock has a market capitalization of $2.21 billion, a PE ratio of -20.74 and a beta of -1.25. The stock’s 50 day moving average price is $12.57 and its 200-day moving average price is $9.67. Day One Biopharmaceuticals, Inc. has a 52-week low of $5.64 and a 52-week high of $21.43.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). The business had revenue of $53.72 million during the quarter, compared to analysts’ expectations of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. Research analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. JonesTrading cut shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating and raised their target price for the stock from $20.00 to $21.50 in a report on Friday, March 6th. Wedbush reissued a “neutral” rating and set a $21.50 price target (down from $30.00) on shares of Day One Biopharmaceuticals in a research report on Monday, March 9th. Zacks Research lowered shares of Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. TD Cowen cut shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $23.75.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.